EUVIMEDEUVIMED entdecken
BeobachtungsstudieEvaluationsstudieOpen Access · CC BY 4.0

Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States

Jennifer R Havens, Shelly-Ann Fluker iD, Jonathan Schimmel, L Madeline McCrary iD, Lesley S Miller iD, Tomoko Udo iD, Yukari C Manabe iD, Anne Luetkemeyer iD, Greer Burkholder, Andrew M Moon iD, Cody A Chastain iD, Jennifer C Price und 8 weitere

Clinical Infectious Diseases · 23.07.2026 · 83 (1) · e71-e78

DOI: 10.1093/cid/ciag173 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.03.2026. Verfasst von Jennifer R Havens und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Hepatitis C, Hepacivirus, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NICHD NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A major barrier to hepatitis C virus (HCV) elimination in the United States is the lack of a point-of-care test to confirm the presence of HCV RNA. The purpose of this clinical trial was to evaluate the performance of the Xpert® HCV test at CLIA-waived sites in the United States.

Methods

Participants at risk and/or with signs/symptoms of HCV infection provided fingerstick blood that was tested on the Xpert® HCV test and venous blood tested using the cobas® HCV and Elecsys® Anti-HCV II tests. Fingerstick blood was collected at CLIA-waived sites by individuals self-trained on collection procedures.

Results

Participants (N = 1279) were enrolled across 15 sites; 1015 (79.3%) were deemed eligible for further evaluation. Specimens from 985 (97.0%) participants with valid results for Xpert®, cobas and Elecsys were included in the performance analysis. The prevalence of HCV antibodies and HCV RNA was 34.6% and 12.4%, respectively. The Xpert® HCV test demonstrated a positive percent agreement of 93.4% (95% CI: 87.6–96.6) and a negative percent agreement of 99.8% (95% CI: 99.2–99.9) relative to the patient infected status.

Conclusions

Data from this clinical trial showed that the Xpert® HCV test was sensitive, specific, and acceptable for use to detect HCV RNA in human EDTA fingerstick blood from individuals at risk and/or with signs/symptoms of HCV infection. Clinical Trials Registration. This study, Pro0075996, was approved by Advarra IRB (Columbia, Maryland, 21044) and registered on ClinicalTrials.gov (NCT06508996).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis CHepacivirusMolecular Diagnostic TechniquesHumansProspective StudiesUnited StatesFemaleMaleAdultRNA, ViralMiddle AgedSensitivity and SpecificityYoung AdultPoint-of-Care TestingAgedRapid Diagnostic TestsAdolescentHepatitis C Antibodies

Stichwörter der Autor:innen

hepatitis Cpoint-of-careviral RNA

Substanzen

RNA, ViralHepatitis C Antibodies

Autor:innen und Institutionen

  • Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
  • Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Emergency Medicine, Mount Sinai Icahn School of Medicine, NewYork, New York, USA.
  • Department of Medicine, Washington University School of Medicine, St.Louis, Missouri, USA.
  • Department of Health Policy, Management, and Behavior, College of Integrated Health Sciences, University at Albany, Albany, NewYork, USA.
  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Shelly-Ann Fluker, L Madeline McCrary, Lesley S Miller, Tomoko Udo, Yukari C Manabe, Anne Luetkemeyer, Andrew M Moon, Cody A Chastain, John Cafardi, Juan F Gallegos-Orozco, Brittany A Young, Eric Lai

Förderung

  • NIH HHS
  • NICHD NIH HHS
  • NHLBI NIH HHS
  • FDA HHS
  • Centers for Disease Control (CDC)
  • NIBIB NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Havens, J. R., Fluker, S. A., Schimmel, J., McCrary, L. M., Miller, L. S., Udo, T., Manabe, Y. C., Luetkemeyer, A., Burkholder, G., Moon, A. M., Chastain, C. A., Price, J. C., Cafardi, J., Gallegos-Orozco, J. F., Young, B. A., Young, J., Aparicio, C., Song, Y., Lai, E., & Louw, G. E. (2026). Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States. Clinical Infectious Diseases, 83(1), e71-e78. https://doi.org/10.1093/cid/ciag173

Vancouver

Havens JR, Fluker SA, Schimmel J, McCrary LM, Miller LS, Udo T, et al. Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States. Clinical Infectious Diseases. 2026;83(1):e71-e78. doi:10.1093/cid/ciag173

BibTeX
@article{Havens2026,
  author = {Havens, Jennifer R and Fluker, Shelly-Ann and Schimmel, Jonathan and McCrary, L Madeline and Miller, Lesley S and Udo, Tomoko and Manabe, Yukari C and Luetkemeyer, Anne and Burkholder, Greer and Moon, Andrew M and Chastain, Cody A and Price, Jennifer C and Cafardi, John and Gallegos-Orozco, Juan F and Young, Brittany A and Young, Jesse and Aparicio, Carlos and Song, Yu and Lai, Eric and Louw, Gail E},
  title = {Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {83},
  number = {1},
  pages = {e71--e78},
  doi = {10.1093/cid/ciag173}
}
Kostenlos starten →